评价磁刺激作为一种非侵入性技术治疗不同原因的勃起功能障碍:一项前瞻性队列研究。

IF 2.4 3区 医学 Q2 ANDROLOGY
Hasan El-Fakahany, Haythem Bassyouni, Sameh Fayek GamalEl Din, Mahmoud H A Montaser
{"title":"评价磁刺激作为一种非侵入性技术治疗不同原因的勃起功能障碍:一项前瞻性队列研究。","authors":"Hasan El-Fakahany, Haythem Bassyouni, Sameh Fayek GamalEl Din, Mahmoud H A Montaser","doi":"10.1186/s12610-025-00272-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elaboration of alternative therapeutic modality is needed, which should be safer, less costly and with no side effects. Functional Magnetic Stimulator (FMS) is a technique that was approved by the US Food and Drug Administration in 1998. We aimed to evaluate the efficacy of FMS in treating different causes of erectile dysfunction (ED).</p><p><strong>Results: </strong>The mean baseline 15 items of the international index of erectile function (IIEF-15) scores of groups A (arteriogenic ED), B (veno-occlusive ED) and C (psychogenic ED) were 12.8 ± 2.6, 16.2 ± 3.3 and 27.5 ± 3.7, respectively. The mean post sessions IIEF-15 scores of groups A, B and C were 23.4 ± 4.1, 31.5 ± 3.5, 49.2 ± 3.5, respectively. The mean baseline domains of erectile function (EF) scores of groups A, B and C were 3.8 ± 2, 5.8 ± 3.5 and 11.5 ± 3.1, respectively. The mean post sessions domains of EF scores of groups A, B and C were 10.6 ± 3.1, 15 ± 3.6 and 24.8 ± 2.9, respectively. The mean baseline domains of orgasmic function scores of groups A, B and C were 3.3 ± 0.9, 3.9 ± 0.5 and 4.8 ± 0.4, respectively. The mean post sessions domains of orgasmic function scores of groups A, B and C were 4.8 ± 0.8 5.9 ± 1.0 and 8.6 ± 0.5, respectively. The mean baseline domains of sexual desire scores of groups A, B and C were 2.6 ± 0.6, 3.1 ± 0.7 and 4.8 ± 0.7, respectively. The mean post sessions domains of sexual desire scores of groups A, B and C were 3.6 ± 0.5, 4.4 ± 0.7 and 6.6 ± 0.6, respectively. The mean baseline domains of intercourse satisfaction scores of groups A, B and C were 1.9 ± 0.5, 2.4 ± 0.6 and 4.1 ± 0.6, respectively. The mean post sessions domains of intercourse satisfaction scores of groups A, B and C were 2.6 ± 0.5, 3.6 ± 0.5 and 5.5 ± 0.6, respectively. The baseline domains of overall satisfaction scores of groups A, B and C were 1.1 ± 0.3, 1.1 ± 0.3 and 2.4 ± 0.7, respectively. The mean post sessions domains of overall satisfaction scores of groups A, B and C were 2 ± 0.7, 2.7 ± 0.7 and 3.8 ± 0.7, respectively.</p><p><strong>Conclusions: </strong>All patients showed significant improvement regarding domains of the IIEF-15 especially psychogenic cases following the sessions of FMS. Future studies should demonstrate the impact of these sessions on the response of poor responders to phosphodiesterase inhibitors and intracorporeal injections.</p>","PeriodicalId":8730,"journal":{"name":"Basic and Clinical Andrology","volume":"35 1","pages":"26"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180250/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of magnetic stimulation as a non-invasive technique in treating different causes of erectile dysfunction: a prospective cohort study.\",\"authors\":\"Hasan El-Fakahany, Haythem Bassyouni, Sameh Fayek GamalEl Din, Mahmoud H A Montaser\",\"doi\":\"10.1186/s12610-025-00272-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Elaboration of alternative therapeutic modality is needed, which should be safer, less costly and with no side effects. Functional Magnetic Stimulator (FMS) is a technique that was approved by the US Food and Drug Administration in 1998. We aimed to evaluate the efficacy of FMS in treating different causes of erectile dysfunction (ED).</p><p><strong>Results: </strong>The mean baseline 15 items of the international index of erectile function (IIEF-15) scores of groups A (arteriogenic ED), B (veno-occlusive ED) and C (psychogenic ED) were 12.8 ± 2.6, 16.2 ± 3.3 and 27.5 ± 3.7, respectively. The mean post sessions IIEF-15 scores of groups A, B and C were 23.4 ± 4.1, 31.5 ± 3.5, 49.2 ± 3.5, respectively. The mean baseline domains of erectile function (EF) scores of groups A, B and C were 3.8 ± 2, 5.8 ± 3.5 and 11.5 ± 3.1, respectively. The mean post sessions domains of EF scores of groups A, B and C were 10.6 ± 3.1, 15 ± 3.6 and 24.8 ± 2.9, respectively. The mean baseline domains of orgasmic function scores of groups A, B and C were 3.3 ± 0.9, 3.9 ± 0.5 and 4.8 ± 0.4, respectively. The mean post sessions domains of orgasmic function scores of groups A, B and C were 4.8 ± 0.8 5.9 ± 1.0 and 8.6 ± 0.5, respectively. The mean baseline domains of sexual desire scores of groups A, B and C were 2.6 ± 0.6, 3.1 ± 0.7 and 4.8 ± 0.7, respectively. The mean post sessions domains of sexual desire scores of groups A, B and C were 3.6 ± 0.5, 4.4 ± 0.7 and 6.6 ± 0.6, respectively. The mean baseline domains of intercourse satisfaction scores of groups A, B and C were 1.9 ± 0.5, 2.4 ± 0.6 and 4.1 ± 0.6, respectively. The mean post sessions domains of intercourse satisfaction scores of groups A, B and C were 2.6 ± 0.5, 3.6 ± 0.5 and 5.5 ± 0.6, respectively. The baseline domains of overall satisfaction scores of groups A, B and C were 1.1 ± 0.3, 1.1 ± 0.3 and 2.4 ± 0.7, respectively. The mean post sessions domains of overall satisfaction scores of groups A, B and C were 2 ± 0.7, 2.7 ± 0.7 and 3.8 ± 0.7, respectively.</p><p><strong>Conclusions: </strong>All patients showed significant improvement regarding domains of the IIEF-15 especially psychogenic cases following the sessions of FMS. Future studies should demonstrate the impact of these sessions on the response of poor responders to phosphodiesterase inhibitors and intracorporeal injections.</p>\",\"PeriodicalId\":8730,\"journal\":{\"name\":\"Basic and Clinical Andrology\",\"volume\":\"35 1\",\"pages\":\"26\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180250/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Basic and Clinical Andrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12610-025-00272-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ANDROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Andrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12610-025-00272-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:需要进一步研究更安全、成本更低、无副作用的替代治疗方式。功能性磁刺激器(FMS)是美国食品和药物管理局于1998年批准的一项技术。我们的目的是评估FMS治疗不同原因的勃起功能障碍(ED)的疗效。结果:A组(动脉源性ED)、B组(静脉闭塞性ED)和C组(心因性ED)的国际勃起功能指数(IIEF-15)平均基线15项评分分别为12.8±2.6、16.2±3.3和27.5±3.7。A、B、C组术后IIEF-15平均评分分别为23.4±4.1、31.5±3.5、49.2±3.5。A、B、C组的平均基线勃起功能域(EF)评分分别为3.8±2、5.8±3.5和11.5±3.1。A组、B组和C组EF得分的平均后域分别为10.6±3.1、15±3.6和24.8±2.9。A组、B组和C组的性高潮功能平均基线范围分别为3.3±0.9、3.9±0.5和4.8±0.4。A组、B组和C组的性高潮功能后域平均得分分别为4.8±0.8、5.9±1.0和8.6±0.5。A组、B组和C组性欲基线得分均值分别为2.6±0.6、3.1±0.7和4.8±0.7。A组、B组和C组的性欲后域平均得分分别为3.6±0.5、4.4±0.7和6.6±0.6。A组、B组和C组的平均性交满意度基线范围分别为1.9±0.5、2.4±0.6和4.1±0.6。A组、B组和C组的性交后满意度域均值分别为2.6±0.5、3.6±0.5和5.5±0.6。A、B、C组患者总体满意度基线范围分别为1.1±0.3、1.1±0.3、2.4±0.7。A组、B组和C组的总体满意度域平均分别为2±0.7、2.7±0.7和3.8±0.7。结论:所有患者在FMS治疗后IIEF-15的领域均有显著改善,尤其是心因性病例。未来的研究应该证明这些会议对不良反应者对磷酸二酯酶抑制剂和体内注射的反应的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of magnetic stimulation as a non-invasive technique in treating different causes of erectile dysfunction: a prospective cohort study.

Background: Elaboration of alternative therapeutic modality is needed, which should be safer, less costly and with no side effects. Functional Magnetic Stimulator (FMS) is a technique that was approved by the US Food and Drug Administration in 1998. We aimed to evaluate the efficacy of FMS in treating different causes of erectile dysfunction (ED).

Results: The mean baseline 15 items of the international index of erectile function (IIEF-15) scores of groups A (arteriogenic ED), B (veno-occlusive ED) and C (psychogenic ED) were 12.8 ± 2.6, 16.2 ± 3.3 and 27.5 ± 3.7, respectively. The mean post sessions IIEF-15 scores of groups A, B and C were 23.4 ± 4.1, 31.5 ± 3.5, 49.2 ± 3.5, respectively. The mean baseline domains of erectile function (EF) scores of groups A, B and C were 3.8 ± 2, 5.8 ± 3.5 and 11.5 ± 3.1, respectively. The mean post sessions domains of EF scores of groups A, B and C were 10.6 ± 3.1, 15 ± 3.6 and 24.8 ± 2.9, respectively. The mean baseline domains of orgasmic function scores of groups A, B and C were 3.3 ± 0.9, 3.9 ± 0.5 and 4.8 ± 0.4, respectively. The mean post sessions domains of orgasmic function scores of groups A, B and C were 4.8 ± 0.8 5.9 ± 1.0 and 8.6 ± 0.5, respectively. The mean baseline domains of sexual desire scores of groups A, B and C were 2.6 ± 0.6, 3.1 ± 0.7 and 4.8 ± 0.7, respectively. The mean post sessions domains of sexual desire scores of groups A, B and C were 3.6 ± 0.5, 4.4 ± 0.7 and 6.6 ± 0.6, respectively. The mean baseline domains of intercourse satisfaction scores of groups A, B and C were 1.9 ± 0.5, 2.4 ± 0.6 and 4.1 ± 0.6, respectively. The mean post sessions domains of intercourse satisfaction scores of groups A, B and C were 2.6 ± 0.5, 3.6 ± 0.5 and 5.5 ± 0.6, respectively. The baseline domains of overall satisfaction scores of groups A, B and C were 1.1 ± 0.3, 1.1 ± 0.3 and 2.4 ± 0.7, respectively. The mean post sessions domains of overall satisfaction scores of groups A, B and C were 2 ± 0.7, 2.7 ± 0.7 and 3.8 ± 0.7, respectively.

Conclusions: All patients showed significant improvement regarding domains of the IIEF-15 especially psychogenic cases following the sessions of FMS. Future studies should demonstrate the impact of these sessions on the response of poor responders to phosphodiesterase inhibitors and intracorporeal injections.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Basic and Clinical Andrology
Basic and Clinical Andrology Medicine-Urology
CiteScore
3.50
自引率
0.00%
发文量
21
审稿时长
22 weeks
期刊介绍: Basic and Clinical Andrology is an open access journal in the domain of andrology covering all aspects of male reproductive and sexual health in both human and animal models. The journal aims to bring to light the various clinical advancements and research developments in andrology from the international community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信